The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Previous work demonstrated that intestinal cholesterol absorption and regulated expression of intestinal Niemann-Pick C1-like 1 and ATP-binding cassette protein A1 are required for liver X receptor (LXR) agonist-mediated increases in high-density lipoprotein biogenesis. We re-examined those conclusions in mice with intestine-specific deletion of the microsomal triglyceride transfer protein (MTTP-IKO), where chylomicron formation is eliminated. Methods and Results-MTTP-IKO mice demonstrated sustained ≈90% reduction in cholesterol absorption and >80% reduction in Niemann-Pick C1-like 1 expression, yet LXR agonist treatment increased serum high-density lipoprotein and upregulated intestinal ATP-binding cassette protein A1 expression. Hepatic lipogenesis and triglyceride content increased with LXR agonist treatment in both genotypes. Biliary cholesterol secretion was increased in MTTP-IKO mice without further increase upon LXR agonist administration. LXR agonist treatment caused a paradoxical increase in cholesterol absorption in MTTP-IKO mice and decreased fecal neutral sterol excretion, but to levels that still exceeded fecal neutral sterol excretion in LXR agonist-treated control mice. Finally, MTTP-IKO mice demonstrated indistinguishable patterns of increased cholesterol turnover and efflux after intravenous radiolabeled cholesterol administration, with or without LXR agonist treatment. Conclusion-Both intestinal and hepatic cholesterol efflux pathways are basally upregulated in MTTP-IKO mice. Moreover, LXR-dependent pathways modulate intestinal cholesterol absorption, transport, efflux, and high-density lipoprotein production independent of chylomicron assembly and secretion. (Arterioscler Thromb Vasc Biol. 2012;32:1624-1631)
T here is major interest in therapeutic strategies that raise the levels of serum high-density lipoprotein (HDL) cholesterol as an approach to attenuate and reverse atherosclerotic vascular disease. 1 Although the core concepts of reverse cholesterol transport have been discussed for decades, 2 there is renewed interest in the tissue-specific sources of HDL and, in particular, the regulation of intracellular transport pathways involved in promoting cholesterol efflux. 3 HDL formation is dynamically regulated by liver X receptors (LXRα and LXRβ) 4, 5 via transcriptional activation of downstream targets including ATP-binding cassette proteins ABCA1, ABCG1, and ABCG5/G8, each of which modulates key cholesterol efflux pathways and, in turn, participates in the regulation of intestinal cholesterol absorption as well as in reverse cholesterol transport. 6, 7 The therapeutic potential of this approach was highlighted by studies demonstrating that pharmacological LXR agonist activation promotes reverse cholesterol transport. 7 Further studies established a critical role for intestinal (versus hepatic) ABCA1 in HDL biogenesis, 8 whereas more recent studies established a key role of intestinal (versus hepatic and macrophage) LXRα in reverse cholesterol transport, 9, 10 findings that together highlight the importance of intestine-specific cholesterol absorption and efflux pathways in regulating HDL biogenesis and cholesterol homeostasis.
However, several features of LXR agonist-mediated increases in HDL formation and intestinal cholesterol transport and absorption are incompletely understood. Prominent among these is the suggestion that cholesterol absorption per se seems to be required for the HDL-raising effects of LXR agonist treatment, as evidenced by the attenuated responses in mice lacking the recycling transporter Niemann-Pick C1-like 1 (NPC1L1), where cholesterol absorption was greatly reduced and which exhibits both reduced baseline expression of intestinal ABCA1 and a diminished response to LXR agonist treatment. [11] [12] [13] In the present study, we have explored the role of chylomicron (CM)-dependent cholesterol trafficking in response
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Yan Xie, Susan Kennedy, Rohini Sidhu, Jianyang Luo, Daniel S. Ory, Nicholas O. Davidson to LXR agonist treatment. Earlier studies demonstrated that patients with abetalipoproteinemia exhibit dramatically reduced cholesterol absorption, 14 findings phenocopied in mice with conditional intestine-specific deletion of the abetalipoproteinemia gene product, microsomal triglyceride transfer protein (MTTP-IKO). 15 However, the singular importance of CM-dependent intestinal cholesterol transport was called into question by studies demonstrating that MTTP inhibition decreased but did not eliminate intestinal cholesterol transport from enterocytes, with up to 30% of intestinal cholesterol secretion from enterocytes being accounted for by a non-CM (ie, HDL) route. 16 Here we demonstrate that MTTP-IKO mice exhibit LXR dependent modulation of intestinal cholesterol absorption, transport, efflux and HDL production independent of CM assembly and secretion.
Methods
Please see online-only Data Supplement for details of diets, cholesterol absorption, biliary cannulation, cholesterol turnover, analysis of serum, tissue, bile, and fecal lipids, RNA extraction, and quantitative polymerase chain reaction quantitation.
Animals
MTTP-IKO mice were generated as described, with conditional activation of a Villin-Cre-ER T2 fusion gene 17 triggered by intraperitoneal injection of 1 mg tamoxifen (T5648, Sigma, St. Louis, MO) for 5 consecutive days. 15, 18 MTTP-floxed littermates were used as controls. Animals were studied at the indicated intervals in the figure legends after tamoxifen treatment. All animal protocols were approved by the Washington University Animal Studies Committee and conformed to criteria outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
LXR Agonist Treatment
Mice were fed standard mouse chow and at the indicated ages gavaged daily for 7 days with a solution containing either vehicle alone (online-only Data Supplement) or with 25 mg/kg body weight T0901317 (Cayman Chemical Company, Ann Arbor, MI).
Statistical Analyses
All data are shown as mean±SE unless otherwise noted. Statistical comparisons were made using GraphPad Prism 4.0 (GraphPad, San Diego, CA) with 1-way ANOVA for multiple group comparisons and t testing as a post hoc test for comparing different pairs. A value of P<0.05 was considered significant.
Results

No Adaptation in Intestinal Cholesterol Absorption in MTTP-IKO Mice
Because intestinal cholesterol absorption, at least as modeled in vitro, may occur independent of CM secretion, 16 we sought to demonstrate evidence for compensatory adaptation in vivo after intestinal MTTP deletion. However, we found <5% cholesterol absorption at all time points examined ( Figure 1A ) along with consistently elevated fecal fat excretion ( Figure 1B) , suggesting that the phenotypes of defective intestinal lipid transport are maintained for at least 12 weeks after a single cycle of tamoxifen induction. These findings together suggest that intestinal cholesterol transport from the lumen into the systemic circulation is almost completely abrogated in MTTP-IKO mice.
LXR Activation Increases Serum HDL Cholesterol in MTTP-IKO Mice
As predicted, 7 LXR agonist administration to control mice increased serum triglyceride and cholesterol concentrations (Table 1 ), in association with increased cholesterol content of large HDL ( Figure 1C and Figure I in the onlineonly Data Supplement for apolipoprotein content), as well as very low-density lipoprotein (VLDL) triglyceride enrichment ( Figure 1D , right). There was a qualitatively similar response to LXR agonist treatment in MTTP-IKO mice, with increased serum cholesterol and triglyceride concentrations ( Table 1) , an increase in HDL cholesterol ( Figure 1E ), and an increase in VLDL triglyceride ( Figure  1F ). LXR agonist administration resulted in enrichment of the HDL fractions with apolipoprotein E in both genotypes ( Figure I in the online-only Data Supplement). These findings suggest that the HDL raising effect of LXR agonist administration is preserved in mice with virtually no cholesterol absorption.
Conserved, LXR-Dependent Regulation of Genetic Pathways for Intestinal and Hepatic Cholesterol Transport in MTTP-IKO Mice
We next sought to understand some of the mechanisms underlying the response to LXR agonist treatment in MTTP-IKO mice, particularly in the face of attenuated cholesterol absorption. We focused on the expression of NPC1L1 and ABCtype sterol transporters in the small intestine and liver because these have been previously implicated in HDL formation and in response to LXR agonist administration. 8, 11, 19 We found that intestinal NPC1L1 mRNA expression was decreased by >80% in MTTP-IKO mice with no change after LXR agonist treatment (Figure 2A , inset). The expression of ABC transporters (Abca1, Abcg5/8, Abcg1) involved in cholesterol efflux was also suppressed in vehicle-treated MTTP-IKO mice (Figure 2A ), but each of these transporters demonstrated a robust increase in mRNA abundance after LXR agonist administration ( Figure  2A ). It is worth noting the comparable fold induction (average ≈3to 7-fold) between the genotypes of these ABC transporters in response to LXR agonist treatment, despite the reduced overall abundance in treated MTTP-IKO mice compared with treated control mice, findings reminiscent of the observations in NPC1L1 knockout mice after LXR agonist treatment. 11 These data suggest that the regulation of intestinal LXR target genes (including canonical targets such as peroxisome proliferatoractivated receptor-α and sterol regulatory element-binding protein 1c; Table I in the online-only Data Supplement) 20 was for the most part preserved in MTTP-IKO mice.
We also examined the same panel of genes in hepatic extracts from the same groups, which revealed LXRdependent upregulation of Abca1, Abcg5/8, Abcg1, and Pcsk9 mRNA in control mice ( Figure 2B ). Hepatic expression of Abca1 and Abcg5/8 was upregulated in untreated MTTP-IKO mice and increased only slightly with LXR agonist treatment, suggesting distinctive regulation of hepatic cholesterol efflux pathways in the setting of defective CM formation and which was not further modified by LXR agonist administration. A different pattern was observed with hepatic Abcg1, Fas, and sterol regulatory element-binding protein 1c mRNA, in which baseline expression was indistinguishable in both control and MTTP-IKO mice, and LXR agonist treatment induced comparable expression of both targets in both genotypes ( Figure 2B and Table II in the online-only Data Supplement). These findings again emphasize that the response of selected lipid metabolic pathways to LXR agonist administration is preserved in the absence of cholesterol absorption. Among the notable exceptions to this general paradigm was the pattern observed for Pcsk9 and the phospholipid transfer protein, where MTTP-IKO mice demonstrated striking upregulation that was equal to or exceeded that observed in LXR-treated control mice and which was not further increased by LXR agonist treatment ( Figure 2B ).
Intestinal MTTP Deletion Modifies LXR Agonist Modulation of Intestinal and Hepatic Lipid Content
To understand how LXR agonist treatment led to increased HDL levels in mice exhibiting defective CM assembly and severely attenuated cholesterol absorption, we examined intestinal and hepatic lipid content as well as biliary lipid secretion in the various groups of mice. We demonstrated the expected increases in intestinal triglyceride, phospholipid, and free fatty acid content in MTTP-IKO mice, none of which were influenced by LXR agonist treatment ( Table 2 ). The total intestinal cholesterol content was unchanged with LXR agonist treatment in either genotype ( Table 2) , but we found a striking and unanticipated increase in esterified Control (MTTP wild type) and MTTP-IKO mice (n=6-11) were treated with either vehicle (V) or T0901317 (T). Serum total cholesterol (TC), free cholesterol (FC), phospholipids (PL), triglyceride (TG), and free fatty acid (FFA) concentrations were determined (data are expressed as mg/dL except for FAA, mmol/L). The difference between values associated with different superscript letters for the parameters indicated in each vertical column is statistically significant (P<0.05). MTTP-IKO indicates intestine-specific deletion of the microsomal triglyceride transfer protein. Control and MTTP-IKO mice (n=6-11) were treated with either vehicle (V) or T0901317 (T). Tissue total cholesterol (TC), free cholesterol (FC), phospholipids (PL), and triglyceride (TG) were analyzed (see Methods section). Hepatic and intestinal mucosal lipid content was expressed as mean±SE μg/mg protein except for free fatty acid (FFA; nmol/mg protein). The difference between values associated with different superscript letters for the parameters indicated in each vertical column is statistically significant (P<0.05). MTTP-IKO indicates intestine-specific deletion of the microsomal triglyceride transfer protein.
cholesterol in MTTP-IKO mice, an observation we will return to in a later section.
Hepatic triglyceride content was decreased in untreated MTTP-IKO mice compared with control mice (Table 2) , as noted previously. 15 LXR agonist treatment increased hepatic lipogenesis and increased triglyceride content in both genotypes, reaching indistinguishable values in treated control and MTTP-IKO mice ( Table 2 ). These observations are an important departure from findings in LXR agonist-treated NPC1L1 -/mice, which demonstrated attenuated hepatic steatosis and decreased induction of lipogenic mRNAs. 11 The current findings suggest that decreased intestinal cholesterol absorption in the setting of defective CM secretion does not afford protection against hepatic steatosis in LXR agonisttreated MTTP-IKO mice.
Intestinal MTTP Deletion Modifies Both Basal and LXR Agonist Modulation of Biliary Lipid Secretion and Fecal Neutral Sterol Excretion
We next turned to an analysis of potential cholesterol efflux pathways to account for the HDL-raising effects of LXR agonist treatment in MTTP-IKO mice. Biliary cholesterol secretion was increased in LXR agonist-treated control mice, but not to levels observed in untreated MTTP-IKO mice ( Table 3) . Moreover, LXR agonist treatment of MTTP-IKO mice yielded no further increase in biliary cholesterol secretion, findings in accordance with the mRNA expression data for Abcg5/8 alluded to above ( Figure 2B ). We considered the possibility that altered content of an endogenous oxysterol might account for the basal increase in biliary cholesterol secretion, possibly as a result of increased liganding of LXR. 21 To begin exploring this possibility, we examined oxysterol content in control and MTTP-IKO mice, the findings demonstrating increased 25 hydroxycholesterol in livers of MTTP-IKO mice ( Table III in the online-only Data Supplement). These findings, considered together with the increased mRNA expression of hepatic Abcg5/8, raise the possibility that basal alterations in oxysterol content may modulate canalicular cholesterol transporter expression and, in turn, lead to increased biliary cholesterol secretion in MTTP-IKO mice. These changes in hepatic oxysterol content may also explain in part the basal upregulation of hepatic phospholipid transfer protein mRNA expression alluded to above.
We next evaluated the fecal neutral sterol (FNS) output in the various groups to ascertain whether LXR agonist treatment modified net cholesterol efflux in MTTP-IKO mice. LXR agonist treatment increased FNS excretion in control mice, although not to the levels found in untreated MTTP-IKO mice ( Figure 3A) . In contrast, LXR agonist treatment of MTTP-IKO mice led to a significant decrease in FNS excretion ( Figure 3A) . To understand the mechanism for this decrease, we examined cholesterol absorption in the various groups of mice. We found that LXR agonist treatment reduced cholesterol absorption in control mice ( Figure 3B ), as previously demonstrated. [22] [23] [24] In contrast, LXR agonist treatment of MTTP-IKO mice induced a paradoxical increase in cholesterol absorption to levels comparable to those observed in LXR agonist-treated control mice ( Figure 3B ). Thus, despite the virtual elimination of luminal cholesterol absorption under basal conditions, LXR agonist administration to MTTP-IKO mice leads to increased HDL biogenesis and modulates intestinal cholesterol absorption, presumably via CM-independent pathways.
To understand the impact of the changes induced by LXR administration on net cholesterol efflux in the various groups of mice, we administered an intravenous bolus of radiolabeled cholesterol and examined the serum kinetics and cumulative radiolabel recovery in neutral and acidic fractions in feces. The distribution of radiolabeled cholesterol in serum was largely (≈70%) within HDL by 1 day after administration ( Figure IIA in the online-only Data Supplement). LXR administration accelerated the turnover of cholesterol in control mice ( Figure 3C ) and augmented recovery of radiolabeled FNS (Figure 3D ), findings consistent with other studies. 25 However, despite the increase in cholesterol absorption and decreased FNS excretion in LXR-treated MTTP-IKO mice ( Figure 3A and 3B) , cholesterol turnover and cumulative recovery of radiolabeled FNS were similarly increased in MTTP-IKO mice, with or without LXR agonist treatment and if anything, the recovery of radiolabeled FNS tended to be slightly higher in the treated group ( Figure 3C and 3D) . The recovery of radiolabeled bile acids was higher in control compared with MTTP-IKO mice and was unchanged by LXR agonist treatment ( Figure 3E ). Residual radiolabeled cholesterol and bile acid were determined in the liver at euthanization, the findings again reflecting decreased cholesterol and bile acid in LXR agonist-treated control mice and in MTTP-IKO mice with or without LXR agonist treatment ( Figure IIB and IIC in the online-only Data Supplement).
Taken together, the findings suggest that augmented cholesterol efflux in MTTP-IKO mice is mediated at least in part through upregulation of canalicular cholesterol export, coupled with the almost complete elimination of lumen to serum cholesterol transport. The findings further suggest that LXR agonists increase HDL biogenesis and modulate intestinal cholesterol absorption and flux in MTTP-IKO mice through pathways that are independent of CM assembly and secretion.
Discussion
A confluence of recent studies has highlighted the importance of intestine-specific LXR activation in promoting cholesterol efflux. 9, 10, 26 Although it is clear that the small intestine plays a critical role in both cholesterol absorption and efflux as well as in HDL biogenesis, the precise interactions of the various pathways involved along with their metabolic regulation are incompletely understood. Here, we show that LXR activation increases HDL biogenesis in MTTP-IKO mice through mechanisms independent of the intestinal CM assembly and despite the virtual elimination of cholesterol absorption. These findings were unanticipated in view of studies showing that intestinal cholesterol absorption per se seems to be required for the HDL-raising effects of LXR agonist treatment, as evidenced by the attenuated responses in NPC1L1 knockout mice, where cholesterol absorption was greatly reduced. 11 The observation that LXR agonist treatment augments HDL biogenesis in MTTP-IKO mice raises some important questions, including just how LXR activation might promote HDL production in the virtual absence of intestinal cholesterol absorption and from exactly which tissue and metabolic pool does this cholesterol arise? It is worth noting that our studies were conducted using a general rather than intestinespecific LXR agonist, 10, 27 but several findings point to an effect mediated through intestinal LXR in MTTP-IKO mice. These include the significant upregulation of intestinal Abca1 and Abcg1 expression in LXR agonist-treated MTTP-IKO mice, which would be anticipated to augment cholesterol delivery into the systemic compartment; the small yet significant increase in apparent cholesterol absorption in LXR agonisttreated MTTP-IKO mice inferred from the dual fecal isotope data along with decreased FNS excretion in these animals. It is worth pointing out that the expression of Abcg1 mRNA (as inferred from the quantitative polymerase chain reaction crossing threshold in our study) in enterocytes and hepatocytes is quite low, findings in line with other observations, 28 and thus the upregulation of Abcg1 mRNA after LXR agonist treatment should be interpreted with caution. Nevertheless, the findings together strongly imply that elements of intestinal cholesterol uptake and efflux are indeed regulated by LXR agonist administration, yet in a manner that is independent from CM assembly and secretion. Earlier studies, using MTTP inhibitor-treated rat enterocytes and intestine-like cell lines, indicated the possibility of non-CM, and apolipoprotein B-independent pathways of cholesterol transport might account for up to 30% of intestinal cholesterol secretion, and further suggested that these pathways may be independently regulated. 16, 29 The current findings offer insights that both extend and contrast with those studies. Specifically, our results do not support the suggestion that intestinal cholesterol absorption occurs to any measurable extent in vivo (<5% likely representing the lower detectable limit of this method) in the absence of CM formation. Nevertheless, the findings in LXR agonist-treated MTTP-IKO mice are broadly consistent with findings that suggest a non-CM route for cholesterol transport from the enterocyte to the systemic circulation.
In considering the mechanisms whereby LXR agonist administration leads to intestinal cholesterol mobilization and augmented HDL biogenesis in MTTP-IKO mice, one possibility is the small increase in de novo or newly absorbed cholesterol noted above in these animals as evidenced by the apparent increase in cholesterol absorption in LXR agonisttreated MTTP-IKO mice ( Figure 3B ). Another possibility is that LXR administration leads to mobilization of an existing or preabsorbed pool of intestinal cholesterol. One of the unanticipated findings in the current studies was the basal increase in intestinal mucosal cholesterol content in MTTP-IKO mice which was almost completely accounted for by an ≈6-fold increase in cholesterol ester accumulation ( Table 2 ). These findings are an important departure from other studies in which intestinal MTTP was inducibly deleted in vivo, where those authors demonstrated a 60% reduction in intestinal cholesterol ester content and a 29% increase in free cholesterol. 29 It is worth pointing out, however, that those studies were conducted using the Mx1 Cre line (which deletes hepatic and to some extent intestinal MTTP) in an LDL receptor knockout background, rather than the model used in the current studies. 29 Nevertheless, while the explanation for the discrepancy in intestinal cholesterol ester accumulation between the 2 lines of mice is yet to be explored, it might be reasonable to speculate that LXR administration augments mobilization of a preformed and expanded enterocyte pool of cholesterol in our line of MTTP-IKO mice. Although not measured directly in our studies, intestinal cholesterol synthesis as inferred by the expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase mRNA was slightly reduced in MTTP-IKO mice both at baseline and after LXR administration ( Table I in the onlineonly Data Supplement) , making it less likely that upregulation of newly synthesized intestinal cholesterol might account for the HDL cholesterol-raising effects of LXR administration.
It is also worth considering the possibility that LXR agonist administration led to systemic mobilization of hepatic cholesterol in MTTP-IKO mice, in addition to the sustained increase in canalicular cholesterol output. Our prior studies indicated that hepatic lipogenesis and VLDL secretion were increased in MTTP-IKO mice, 15 and the current studies suggest that some of the pathways involved may share LXR-dependent regulation. Examples include the baseline upregulation of the canalicular cholesterol export heterodimeric subunits Abcg5/8 as well as sterol regulatory element-binding protein 1c and phospholipid transfer protein. 30, 31 Our studies also suggest that the adaptive alterations in hepatic lipid metabolism in MTTP-IKO mice include increased abundance of oxysterols, including known LXR ligands. 21 LXR agonist administration led to a further increase in some (Abca1, Abcg1, Abcg5/8) of the genes involved in cellular cholesterol efflux, consistent with previous studies demonstrating that the synthetic LXR agonist is a more potent ligand than the endogenous oxysterols examined. However, while not discounting the formal possibility that the increase in HDL might be accounted at least in part from hepatic sources, it is worth noting that the dominant pathway for increased cholesterol efflux in MTTP-IKO mice, in both basal and LXR-treated conditions, appears to be via canalicular secretion. The overwhelming importance of the biliary secretion pathway is emphasized by the negligible effects of LXR agonist administration on the kinetics of cholesterol turnover and efflux in MTTP-IKO mice, suggesting that the small increase in cholesterol absorption and decreased FNS excretion are more than offset by the continued increase in canalicular cholesterol secretion coupled with decreased cholesterol absorption in the setting of defective intestinal CM secretion and lipid export.
In summary, the current findings illustrate the complex and interrelated pathways that modulate cholesterol efflux pathways in vivo. The observation that canalicular cholesterol secretion is dramatically enhanced in the setting of defective intestinal CM assembly and the virtual elimination of cholesterol absorption suggests the possibility that strategies for intestine-specific MTTP inhibition may be attractive considerations by which to promote cholesterol efflux. This strategy would have direct appeal in the setting of elevated LDL cholesterol levels, and it would be interesting to examine whether a similar response to that observed in the present study would be observed in LDL receptor null mice. The additional observation that LXR agonist administration leads to increased HDL biogenesis in the absence of CM secretion reinforces the notion that intestine-specific LXR agonists may have utility even in the absence of cholesterol absorption.
